Repository
A central hub that connects important questions, data and methods, making it easier to find and use the right information.
EU-funded · Horizon Europe · Grant 101137141
Advancing paediatric and orphan drug development through modelling and simulation
ERAMET builds a transparent European ecosystem where developers and regulators use modelling & simulation, artificial intelligence and real-world data to make better decisions about medicines for children and people with rare diseases.
What is ERAMET?
An acronym with a long name and a simple aim
ERAMET stands for Ecosystem for Rapid Adoption of Modelling and Simulation Methods to Address Regulatory Needs in the Development of Orphan and Paediatric Medicines.
The project supports the development of orphan and paediatric medicines through an integrated approach that helps developers and regulators make informed drug development and assessment decisions. It promotes innovative methods such as modelling and simulation, AI and real-world data to advance regulatory science across Europe.
Read more about the projectOur objective
To create a comprehensive system that aids the development and regulatory approval of drugs for children and rare diseases, helping both developers and regulators make better decisions using advanced modelling and simulation and real-world data such as medical records and registries.
- Question-centric approach to drug development
- Credibility assessment of data and methods
- Faster, more reliable regulatory decisions
The three pillars
How the ecosystem is built
Standards development
Establishing and validating high-quality standards for data and analytical methods, including digital twins, AI and hybrid approaches that combine different types of data and analyses.
AI-based platform
An advanced platform that automates data collection, formatting and analysis using M&S, and assesses the credibility of the data and methods used to ensure reliability and accuracy.
Latest
News & updates
ERAMET contributes to TEDDY panel on innovative methodologies for paediatric and rare disease drug development
ERAMET will contribute to the TEDDY General Assembly and Scientific Meeting 2026 through a dedicated panel on how innovative methodologies can stre…
A consortium of 17 partners across Europe
Explainer
What are modelling and simulation methods?
Modelling and simulation (M&S) methods use computational and mathematical techniques to replicate biological systems, disease progression and drug interactions, helping predict outcomes, optimise treatments and reduce reliance on clinical trials.
Pharmacokinetic and pharmacodynamic models simulate drug absorption and effects, agent-based models study disease spread and patient behaviour, and machine-learning techniques predict treatment responses for personalised medicine.
Stakeholder network